Prevention or Treatment of Ards With Aspirin
- 1 January 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Shock
- Vol. 47 (1) , 13-21
Abstract
Background: The acute respiratory distress syndrome (ARDS) is a life-threating disorder that contributes significantly to critical illness. No specific pharmacological interventions directed at lung injury itself have proven effective in improving outcome of patients with ARDS. Platelet activation was identified as a key component in ARDS pathophysiology and may provide an opportunity for preventive and therapeutic strategies. We hypothesize that use of acetyl salicylic acid (ASA) may prevent and/or attenuate lung injury. Methods: We conducted a systematic review of preclinical studies and meta-analysis of clinical studies investigating the efficacy of ASA in the setting of lung injury. Medline, embase, and cochrane databases were searched. Results: The literature search yielded 1,314 unique articles. Fifteen preclinical studies and eight clinical studies fulfilled the in- and exclusion criteria. In the animal studies, the overall effect of ASA was positive, e.g., ASA improved survival and attenuated inflammation and pulmonary edema. Mechanisms of actions involved, among others, are interference with the neutrophil-platelets interaction, reduction of leukotrienes, neutrophil extracellular traps, and prostaglandins. High-dose ASA may be the drug of choice. A meta-analysis of three clinical studies showed an association between ASA use and a reduced incidence of ARDS (OR 0.59, 95% CI 0.36–0.98), albeit with substantial between-study heterogeneity. All studies had their own shortcomings in methodological quality. Conclusion: This systematic review of preclinical studies and meta-analysis of clinical studies suggests a beneficial role for ASA in ARDS prevention and treatment. However, the currently available data is insufficient to justify an indication for ASA in ARDS. The body of literature does support further studies in humans. We suggest clinical trials in which the mechanisms of action of ASA in lung injury models are being evaluated to guide optimal timing and dose, before prospective randomized trials.Keywords
This publication has 63 references indexed in Scilit:
- Lung Injury Prevention with Aspirin (LIPS-A): a protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injuryBMJ Open, 2012
- Platelets induce neutrophil extracellular traps in transfusion-related acute lung injuryJournal of Clinical Investigation, 2012
- Disruption of Platelet-derived Chemokine Heteromers Prevents Neutrophil Extravasation in Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Do Aspirin and Other Antiplatelet Drugs Reduce the Mortality in Critically Ill Patients?Thrombosis, 2011
- Association of prehospitalization aspirin therapy and acute lung injury: Results of a multicenter international observational study of at-risk patients*Critical Care Medicine, 2011
- Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*Critical Care Medicine, 2011
- Lipoxins: resolutionary roadBritish Journal of Pharmacology, 2009
- 15-Epi-lipoxin A4 Inhibits Myeloperoxidase Signaling and Enhances Resolution of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Neutrophil Extracellular Traps Kill BacteriaScience, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003